Solid Tumours Clinical Trial
Official title:
An Open-Label, Non-randomised, Parallel Group, Multicentre, Phase I Study to Assess the Safety and Effect of Olaparib at Steady State on the Pharmacokinetics of the Anti-hormonal Agents Anastrozole, Letrozole and Tamoxifen at Steady State, and the Effect of the Anti-hormonal Agents on Olaparib, Following Administration in Patients With Advanced Solid Cancer
Verified date | September 2019 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label 2-part Phase I study in patients with advanced solid tumours. Part A of the study (mandatory) will assess the effect of olaparib on the pharmacokinetics (PK) of anastrozole, letrozole and tamoxifen and vice versa; Part B will allow patients (if eligible) continued access to olaparib after the PK phase and will provide additional safety data.
Status | Completed |
Enrollment | 79 |
Est. completion date | April 29, 2019 |
Est. primary completion date | April 30, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 130 Years |
Eligibility |
Inclusion Criteria: 1. Provision of written informed consent prior to any study specific procedures 2. Male or female aged =18 years 3. Histological or cytological confirmation of any malignant solid tumour in an advanced or metastatic setting who meet one of the criteria below: - Patients should be resistant or refractory to standard treatment if such treatment exists OR - Patients for which no suitable effective standard therapy exists OR - Patients with advanced breast cancer for whom anastrozole, letrozole or tamoxifen are indicated may also enter the study (postmenopausal breast cancer patients will be eligible for any of the cohorts; however, premenopausal breast cancer patients will be eligible for the tamoxifen cohort only). 4. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below: - Haemoglobin (Hb) =10.0 g/dL with no blood transfusions in the past 28 days - Absolute neutrophil count (ANC) =1.5 x 109/L - Platelet count =100 x 109/L - Total bilirubin =1.5 x institutional upper limit of normal (ULN) (except in the case of Gilbert's disease) - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =2.5 x institutional ULN unless liver metastases are present, in which case they must be =5x ULN - Serum creatinine =1.5 x institutional ULN 5. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 6. Patients must have a life expectancy =16 weeks 7. Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day 1 of Part A. Postmenopausal is defined as: - Age = 60 years - Age <60 years and amenorrheic for 1 year or more in the absence of chemotherapy and/or hormonal treatment - Luteinising hormone (LH), follicle stimulating hormone (FSH) and plasma oestradiol levels in the postmenopausal range for women under 60 years - Radiation-induced oophorectomy with last menses >1 year ago - Or surgical sterilisation (bilateral oophorectomy or hysterectomy) 8. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment, and scheduled visits and examinations 9. Patients must be on stable concomitant medication regimen (with the exception of electrolyte supplements), defined as no change in medication or dose within 2 weeks prior to start of study treatment. Exclusion Criteria: 1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, its agents, and/or staff at the study site) 2. Previous enrolment in the present study 3. Exposure to an investigational product (IP) (including PARP inhibitor) within 30 days or 5 half lives (whichever is the longer) prior to enrolment 4. Prior chemotherapy within 3 weeks of study entry 5. Prior radiotherapy within 2 weeks of study entry 6. If prior endocrine treatment is given, adequate washout period is required: at least 2 weeks for anastrozole, at least 4 weeks for letrozole and at least 10 weeks for tamoxifen 7. Resting ECG with QTc >470 msec detected on 2 or more time points within a 24 hour period, or family history of long QT syndrome. If ECG demonstrates QTc >470 msec, patient will be eligible only if repeat ECG demonstrates QTc <470 msec. 8. Patients who are receiving inhibitors or inducers of CYP3A4 unless washed out prior to start of study treatment. 9. Persistent toxicities (Common Toxicity Criteria for Adverse Events [CTCAE] grade =2) caused by previous cancer therapy, excluding alopecia and/or CTCAE grade 2 peripheral neuropathy 10. Patients with myelodysplastic syndrome/acute myeloid leukaemia 11. Major surgery within 2 weeks of starting study treatment: patients must have recovered from any effects of any major surgery 12. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled seizures or active uncontrolled infection. 13. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with absorption of the study medication 14. Patients who have gastric, gastro-oesophageal, or oesophageal cancer 15. Pregnant or breastfeeding women 16. Patients with known active Hepatitis B or C, or human immunodeficiency virus (HIV). 17. Patients with a known hypersensitivity to olaparib (all cohorts), tamoxifen (Cohort 1) anastrozole (Cohort 2), letrozole (Cohort 3), or any of the excipients of these products. |
Country | Name | City | State |
---|---|---|---|
Belgium | Research Site | Brussels | |
Belgium | Research Site | Edegem | |
Belgium | Research Site | Gent | |
Belgium | Research Site | Leuven | |
Belgium | Research Site | Liège | |
Belgium | Research Site | Wilrijk | |
Denmark | Research Site | Herlev | |
France | Research Site | Bordeaux | |
Netherlands | Research Site | Amsterdam | |
Netherlands | Research Site | Utrecht | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Manchester | |
United Kingdom | Research Site | Newcastle Upon Tyne | |
United Kingdom | Research Site | Sutton |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Belgium, Denmark, France, Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effect of Olaparib on Exposure to Tamoxifen - Cmax ss | Tamoxifen, N-desmethyl tamoxifen (N-DMT) and endoxifen Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios | Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31 | |
Primary | Effect of Tamoxifen on Exposure to Olaparib - Cmax ss | Olaparib Cmax ss in the presence and absence of co-administered tamoxifen, and associated Cmax ss treatment ratios | Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31 | |
Primary | Effect of Olaparib on Exposure to Anastrozole - Cmax ss | Anastrozole maximum plasma concentration at steady state (Cmax ss) in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios | Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24 | |
Primary | Effect of Anastrozole on Exposure to Olaparib - Cmax ss | Olaparib Cmax ss in the presence and absence of co-administered anastrozole, and associated Cmax ss treatment ratios | Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24 | |
Primary | Effect of Olaparib on Exposure to Letrozole - Cmax ss | Letrozole Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios | Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43 | |
Primary | Effect of Letrozole on Exposure to Olaparib - Cmax ss | Olaparib Cmax ss in the presence and absence of co-administered letrozole, and associated Cmax ss treatment ratios | Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43 | |
Primary | Effect of Olaparib on Exposure to Tamoxifen - AUC0-t | Tamoxifen, N-DMT and endoxifen AUC0-t, in the presence and absence of co-administered olaparib, and associated AUC0-t treatment ratios | Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31 | |
Primary | Effect of Tamoxifen on Exposure to Olaparib - AUC0-t | Olaparib AUC0-t, in the presence and absence of co-administered tamoxifen, and associated AUC0-t treatment ratios | Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31 | |
Primary | Effect of Olaparib on Exposure to Anastrozole - AUC0-t | Anastrozole Area under plasma concentration-time curve over the dosing interval at steady state (AUC0-t), in the presence and absence of co-administered olaparib, and associated AUC0-t treatment ratios | Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24 | |
Primary | Effect of Anastrozole on Exposure to Olaparib - AUC0-t | Olaparib AUC0-t, in the presence and absence of co-administered anastrozole, and associated AUC0-t treatment ratios | Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24 | |
Primary | Effect of Olaparib on Exposure to Letrozole - AUC0-t | Letrozole AUC0-t, in the presence and absence of co-administered olaparib, and associated AUC0-t treatment ratios | Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43 | |
Primary | Effect of Letrozole on Exposure to Olaparib - AUC0-t | Olaparib AUC0-t, in the presence and absence of co-administered letrozole, and associated AUC0-t treatment ratios | Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03315091 -
Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT01921140 -
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT00732420 -
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03572192 -
Tissue Collection Framework To Improve Outcomes In Solid Tumours
|
||
Completed |
NCT02360345 -
Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly
|
Phase 1 | |
Completed |
NCT02264418 -
Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT01956669 -
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
|
Phase 2 | |
Recruiting |
NCT02263950 -
A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Recruiting |
NCT02215850 -
Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT01900028 -
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT01931761 -
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
|
Phase 1 | |
Completed |
NCT00136578 -
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT01184274 -
A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
|
Phase 1 | |
Withdrawn |
NCT03266159 -
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT01894256 -
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
|
Phase 1 | |
Completed |
NCT01974349 -
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT02923947 -
Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment
|
Phase 1 | |
Completed |
NCT02056392 -
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT02063204 -
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
|
Phase 1 | |
Completed |
NCT00742131 -
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
|
Phase 1 |